Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

Efe, Cumali; Hagstrom, Hannes; Ytting, Henriette; Bhanji, Rahima; Muller, Niklas; Wang, Qixia; PÜRNAK, TUĞRUL; Muratori, Luigi; Werner, Marten; Marschall, Hanns-Ulrich; Muratori, Paolo; GÜNŞAR, FULYA; Klintman, Daniel; Pares, Albert; Heurgue-Berlot, Alexandra; Schiano, Thomas; Cengiz, MUSTAFA; Tana, Michele; Ma, Xiong; Montano-Loza, Aldo; Berg, Thomas; Verma, Sumita; Larsen, Fin; Ozaslan, Ersan; Heneghan, Michael; Yoshida, Eric; Wahlin, Staffan

doi:10.1016/j.cgh.2017.06.001

Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

Efe C., Hagstrom H., Ytting H., Bhanji R. A., Muller N. F., Wang Q., ...Daha Fazla

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, cilt.15, sa.12, ss.1950-1957, 2017 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 15 Sayı: 12
Basım Tarihi: 2017
Doi Numarası: 10.1016/j.cgh.2017.06.001
Dergi Adı: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1950-1957
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Evet

Özet

BACKGROUND & AIMS: Predniso(lo) ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH.